For the past two years, providers have fielded the same question from patients again and again: where can I get peptides from a source I can trust? Until now, the honest answer for many of the most-requested compounds was complicated.

On October 28, 2026, the U.S. Department of Health and Human Services gave that conversation a new starting point. HHS announced it will use enforcement discretion for six peptides, opening a near-term path for state-licensed 503A compounding pharmacies to prepare them for individual patients with a valid prescription while the FDA works through formal rulemaking.

As a 503A compounding pharmacy based in Houston and licensed in 40+ states, Southend Pharmacy has been tracking this matter since the FDA’s July advisory committee meeting. Here is what the announcement says, what it leaves open, and the questions we expect providers to be weighing.

What HHS announced

In a policy issued October 28, HHS said it does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound six peptides not yet on the FDA’s 503A bulk drug substances list, as long as specific conditions are met The six are:

• BPC-157
• Epitalon
• KPV
• MOTS-c
• Semax
• TB-500

The list tracks the July 23–24, 2026 meeting of the FDA’s Pharmacy Compounding Advisory Committee (PCAC). That panel recommended adding these six to the bulks list and voted against a seventh, Emideltide (DSIP). Several of those votes were close, with BPC-157, KPV and TB-500 each passing 8–6.The FDA’s drug review center (CDER) had recommended against listing each of the six.

PCAC recommendations are advisory. Formally adding a substance to the bulks list still requires the FDA to propose a rule, take public comment and publish a final rule. Enforcement discretion is the bridge HHS chose to use while that process runs.

What enforcement discretion changes, and what it leaves in place

Enforcement discretion is an agency decision to hold off on specific enforcement actions under defined conditions. It opens a prescription-based channel through licensed 503A pharmacies, and the underlying statute stays exactly as written.

A few points are worth keeping in view:

• Compounded versions of these peptides are not FDA-approved, which means FDA has not reviewed their safety, effectiveness or quality. None of the six are on the 503A Bulks List, and the interim policy does not change that. 
• The policy is interim. It applies while rulemaking continues, and the final rule could look different from today’s arrangement. HHS has also said it may revisit the policy, in whole or in part, if a safety signal or product quality issue arises. 
• 503A requirements still apply. Compounding stays tied to a valid prescription for an individual patient, along with each state’s pharmacy board rules.

The pathway now exists, and the conditions attached to it are a central part of the story.

New quality and reporting conditions 

The policy sets conditions for pharmacies that choose to compound these peptides. Among them:

• Sourcing and Testing. . The bulk peptide must come from an FDA-registered, cGMP compliant manufacturer, with a certificate of analysis (COA) for each batch documenting identity, purity, potency and contaminant testing. 
• Reporting. Pharmacies report serious adverse events and product quality issues to FDA’s MedWatch program and to the relevant states, along with information on the compounded product. 
• Single Ingredient. Each compounded product may contain only one of the six peptides 
• Route of Administration. Each peptide is limited to specific routes of administration. For example, Semax is limited to intranasal use, and KPV to topical and oral forms. 
• Packaging and Labeling. The delivery device that may be packaged with the product is an FDA 510(k)-cleared syringe and the label must state “This is a compounded drug product. Not for resale.” 

These conditions put the spotlight on the pharmacy behind the prescription. Sourcing documentation, testing practices and reporting workflows are now part of the baseline expectation for any 503A partner working in this category.

Why this matters: the gray market problem

Patient demand for peptides has grown faster than the regulated supply. Much of what fills that gap is sold online labeled “for research use only,” a workaround sellers use to claim the products aren’t intended for people. Those products sit outside the prescription and pharmacist oversight that 503A compounding requires.

HHS framed the enforcement discretion policy as one way to pull patients away from that market and toward pharmacy-prepared products. 

Southend’s perspective as a 503A pharmacy

Southend Pharmacy is following this regulatory path closely, from the July PCAC meeting through the October 28th policy, and covered it in depth in our webinar The Evolving Peptide Landscape with James LaValle.

While Southend does not currently compound any of the six peptides, we are however preparing to offer them in the near future as regulation allows. Currently, our team is reviewing the full policy now, including its sourcing, testing and reporting conditions. We will share updates on timing and availability with our provider partners directly.

What stays constant is how we work: prescription-based 503A compounding from our Houston facility, licensure across 40+ states, and partnership with the licensed providers who make every clinical decision for their patients.

This article is for general information only and is not legal, regulatory or medical advice. Prescribing decisions rest with the licensed provider. Regulatory status may change; refer to HHS and FDA for the current policy. 

Important information

Compounded medications are not reviewed or verified by the FDA for safety, effectiveness, or quality and are not FDA-approved. Instead, compounded drugs may be prepared in certain circumstances – for example, when patients cannot be treated with an FDA-approved medication. In situations like this, compounding can serve important patient needs. A licensed healthcare provider will evaluate if treatment involving a compounded medication is necessary or appropriate for the patient. 503A pharmacies are required to comply with applicable federal and state laws, rules, regulations, and guidance.

Sources

• HHS temporarily allows compounding pharmacies to make six peptides (iHeart, Oct 28, 2026)
• Peptides at a crossroads: what wellness providers need to know (Holland & Knight, Oct 2026)
• FDA sends peptide interim access policy to White House for review (AmSpa)
• FDA scientists flag concerns with peptides (NPR, Jun 30, 2026)